Eating Grass
24 Sep 2016
Re: Friday close We are in an uptrend so price goes up on a Friday pm. Not sure how long this will continue. There seems to be some serious stake building. I have long been a fan of Abcam in contrast to many brokers who cannot understand the company when they benchmark it against other companies in the biotech market. ABC is a wonderful hybrid of bio science + marketing. Personally I don't feel the market makers are manipulating prices, nor do I detect significant insider trading before results are publishedThe NED Dr Jonathan Milner is the biggest stake holder. He is downsizing but I cannot blame him as his paper wealth here is 176 million quid. This explains why ABC stays in AIM because otherwise there would be a lot of CG tax to pay if selling from the main market.Dr Milner's total direct and indirect interest in the Company has decreased by 1,330,731 Ordinary Shares (including sale of the 20,361 Ordinary Shares resulting from the recent exercise of the share options) to a total of 21,994,934 Ordinary Shares, representing approximately 10.84% of the Company's issued share capital.
kilindidni
18 Sep 2016
Friday close Any views on closing activity towards end of trading?
LK Hyman
12 Sep 2016
Re: Lookin' good Grass,"PE now quite giddy at 42"It is, but I don't think that a fast growing company ought to be valued on the same PE basis as an ex growth company. If, for example (a big if, I grant you) ABC grew its earnings at 10% a year for 5 years the PE would ceteris paribus fall to 26. Still high, but not stratospheric.There are plenty of pretty staid companies around that sell on high PEs because they are perceived to be fine companies .... ABF for example, notwithstanding today's fall in the share price.LKH on the flybridge
Eating Grass
12 Sep 2016
Re: Lookin' good Glad you like the numbers LKH.PE now quite giddy at 42 but no one wants to sell!Abcam is well diversified both in products and geographically.This is a genuine growth industry.
Sambram
12 Sep 2016
Re: Lookin' good "A strong set of results from Abcam in line with revenues and slightly better profitability as expected. Investment remains the theme, with a focus on growth in existing product lines, addition of new product lines and still looking to acquire new technologies. An ambitious statement, and underpinned by the need to scale the existing business to support the growth targets. In our view the ambition is in the price, though not the increased risk to get there."Panmure hesitant this morning, taken from Research Tree
once a week
12 Sep 2016
Re: Lookin' good yes, good results. Growth in all areas and confident statements. EPS unchanged due to R&D investments - which is one of the best reasons in my book.
LK Hyman
12 Sep 2016
Lookin' good The results look pretty good. Although EPS was unchanged revenue was well ahead and the balance sheet remains rock solid, with net cash. Divi twice covered and although the yield is pretty nugatory the prospects look first rate, especially in China.This is a keeper.LKH on the flybridge
Eating Grass
02 Aug 2016
Re: Firefly shining bright Thanks LKH. I gave up any lab work in the 1970s but to me it seems incredibly neat that Firefly can detect around 60 microRNAs with a standard lab flow cytometer (fancy machine that detects glowing particles) in just 1 drop of blood or serum. Firefly uses individual detector molecules are labelled with various fluorescent dyes much like barcodes. You can choose which mRNAs to make a custom panel. Clever to be able to detect trace quantities of molecules in such tiny samples. Scientists have yet to take much advantage of this new arena - so ABC is offering lots of hand-holding e.g. free "discovery program" to link into scientific literature and also offering the services of their own lab in the USA to help get scientists started.mRNAs are little molecules that control the action of genes. Knowing which ones are floating around gives an insight into diseases like cancer and inflammation. Currently Firefly, which is patented, is a tiny part of ABC business but it will surely grow. I think the potential is huge and so instead of profit taking I upped my stake in ABC.
LK Hyman
27 Jul 2016
Re: Firefly shining bright Grass,"I see ABC is now offering this for multiplex technology for cytokines as well as miRNA"Hmmm ... Is that good? I love statements such as the above ... makes me realise why I bought this puppy, which has been extremely rewarding notwithstanding my total lack of understanding of what the sam heck their biznay is all about .... rabbits, sheep, petri dishes, white coated pointyhead scientists I dunno.LKH at the LK Wash & Valet proud arts man and ABC shareholder
Eating Grass
27 Jul 2016
Firefly shining bright I predicted Abcam would be using the barcode technology in Firefly for other purposes and sure enough I see ABC is now offering this for multiplex technology for cytokines as well as miRNA so the future is bright. Abcam management seems worried about Brexit but so far no dip in sales. I think any sterling weakness will help sales.
Eating Grass
11 Jul 2016
Is Nessie hiding in this chart? I am not really a chartist but there seem to be several humps and a tail and a rearing head over a 12 month period.
KestleMill
29 Jun 2016
Re: Broken through 700 level It is due to the weakness of the pound. 90% of Abcam's sales are outside the UK. Every time they sell a product in dollars or euros it is now worth significantly more pounds than it was before the referendum.
Eating Grass
28 Jun 2016
Re: Broken through 700 level Abcam is surging because it is a good company with bright prospects. Weak pound not a problem as most products are exported. New CFO comes with excellent pedigree. Maybe Abcam will be swallowed by large group like Thermo Fisher Scientific for a quick gain though my preference is to stay Independent. I would pocket more shares now if I were not already so overweight.
kilindidni
28 Jun 2016
Broken through 700 level Amazing surge upwards, or is it? Any views?
kilindidni
26 Jun 2016
New CFO appointment Interesting choice of new CFO. Apparently well thought of in financial world. Wonder who the runner up was, if any? Still of the view this Company should not remain in the AIM market, despite the financial advantage rad advantages for the earlier shareholders. A company of this size needs to give its shareholders full confidence in its financial practices, IMHO, although I am not suggesting it aims to do otherwise.
